Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib for BRAF-wild-type histiocytoses
2018-002222-23Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in histiocytosis comparing Cobimetinib with Placebo (2 arms). Primary endpoint: Objective metabolic response at month 3 (week 12). Started Dec 2018; status: active.
02
Drugs
cobimetinib
03
Conditions
histiocytosis
Beyond the preview
Go deeper on 2018-002222-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002222-23.